Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

primary progressive MS

3 posts
RRoche
Genentech petrelintide sheds 10.7% weight in Phase II
Read More

Genentech fenebrutinib slashes MS relapses 51%

  • 2026-03-13
03/02/2026 – 01:10 AM – FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by…
RRoche
Roche’s Gazyva Meets Phase III SLE Endpoints at 52 Weeks
Read More

Roche MS drug fenebrutinib cuts relapses 51% in Phase III

  • 2026-03-02
Roche (OTCQX: RHHBY) reported that the pivotal Phase III study FENhance 1 met…
RRoche
Wall Street Just Woke Up to Roche--Here's Why It Could Be Pharma's Next $10 Billion Breakout
Read More

Roche Just Unleashed a Drug That Could Disrupt the Entire MS Market

  • 2026-02-18
This article first appeared on GuruFocus. Roche Holding (RHHBF) could be entering a new growth chapter after unveiling…
Switzerland
www.europesays.com